Fallopian Tube Cancer (Oncology) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fallopian Tube Cancer – Drugs In Development, 2021, provides an overview of the Fallopian Tube Cancer (Oncology) pipeline landscape.Fallopian tube cancer is also called tubal cancer. It develops in the fallopian tubes, which serve as a connection between the ovaries and the uterus. It occurs very rarely. The common symptoms of fallopian tube cancer may include abnormal vaginal bleeding, especially after menopause, abdominal pain or a feeling of pressure in the abdomen, abnormal vaginal discharge that is white, clear or pinkish and a pelvic mass at the time of diagnosis, which is present in up to two-thirds of patients. Usually, cancer metastasizes from other parts of the body such as the ovaries or endometrium to the fallopian tubes. Fallopian tube cancer treatment depends on age, the desire to have children, type and stage of the tumor. It usually involves surgery followed by chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fallopian Tube Cancer – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Fallopian Tube Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Fallopian Tube Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Fallopian Tube Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 4, 25, 89, 74, 4, 16 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 9 and 2 molecules, respectively.

Fallopian Tube Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Fallopian Tube Cancer (Oncology).

– The pipeline guide reviews pipeline therapeutics for Fallopian Tube Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Fallopian Tube Cancer (Oncology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Fallopian Tube Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Fallopian Tube Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Fallopian Tube Cancer (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Fallopian Tube Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

AB Science SA

AbbVie Inc

Acrivon Therapeutics Inc

ADC Therapeutics SA

Advenchen Laboratories LLC

AiVita Biomedical Inc

Akeso Inc

Aldeyra Therapeutics Inc

Amgen Inc

Anew Oncology Inc

Apexigen Inc

APIM Therapeutics AS

Apollomics Inc

Aprea Therapeutics Inc

Aravive Inc

Arch Oncology Inc

Artios Pharma Ltd

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Basilea Pharmaceutica Ltd

Bayer AG

BeiGene Ltd

Bio-Path Holdings Inc

Bio-Thera Solutions Ltd

Laekna Therapeutics Shanghai Co Ltd

Leap Therapeutics Inc

SELLAS Life Sciences Group Inc

Senhwa Biosciences Inc

Shanghai De Novo Pharmatech Co Ltd

Shanghai Haihe Biopharma Co Ltd

Shattuck Labs Inc

Shenzen SiBiono GeneTech Co Ltd

Shenzhen Chipscreen Biosciences Co Ltd

Sierra Oncology Inc

Sotio AS

STADA Pharmaceuticals (Asia) Ltd

Sumitomo Dainippon Pharma Co Ltd

Sutro Biopharma Inc

Synermore Biologics Co Ltd

SynOx Therapeutics Ltd

Tmunity Therapeutics Inc

Transgene SA

Ultimovacs AS

Vascular Biogenics Ltd

Verastem Inc

Viatris Inc

Vigeo Therapeutics Inc

Vyriad Inc

Xencor Inc

Xynomic Pharmaceuticals Holdings Inc

Zentalis Pharmaceuticals Inc

Zymeworks Inc

Table of Contents

Table of Contents

Introduction

Fallopian Tube Cancer - Overview

Fallopian Tube Cancer - Therapeutics Development

Fallopian Tube Cancer - Therapeutics Assessment

Fallopian Tube Cancer - Companies Involved in Therapeutics Development

Fallopian Tube Cancer - Drug Profiles

Fallopian Tube Cancer - Dormant Projects

Fallopian Tube Cancer - Discontinued Products

Fallopian Tube Cancer - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Fallopian Tube Cancer, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Fallopian Tube Cancer – Pipeline by AB Science SA, 2021

Fallopian Tube Cancer – Pipeline by AbbVie Inc, 2021

Fallopian Tube Cancer – Pipeline by Acrivon Therapeutics Inc, 2021

Fallopian Tube Cancer – Pipeline by ADC Therapeutics SA, 2021

Fallopian Tube Cancer – Pipeline by Advenchen Laboratories LLC, 2021

Fallopian Tube Cancer – Pipeline by AiVita Biomedical Inc, 2021

Fallopian Tube Cancer – Pipeline by Akeso Inc, 2021

Fallopian Tube Cancer – Pipeline by Aldeyra Therapeutics Inc, 2021

Fallopian Tube Cancer – Pipeline by Amgen Inc, 2021

Fallopian Tube Cancer – Pipeline by Anew Oncology Inc, 2021

Fallopian Tube Cancer – Pipeline by Apexigen Inc, 2021

Fallopian Tube Cancer – Pipeline by APIM Therapeutics AS, 2021

Fallopian Tube Cancer – Pipeline by Apollomics Inc, 2021

Fallopian Tube Cancer – Pipeline by Aprea Therapeutics Inc, 2021

Fallopian Tube Cancer – Pipeline by Aravive Inc, 2021

Fallopian Tube Cancer – Pipeline by Arch Oncology Inc, 2021

Fallopian Tube Cancer – Pipeline by Artios Pharma Ltd, 2021

Fallopian Tube Cancer – Pipeline by Astellas Pharma Inc, 2021

Fallopian Tube Cancer – Pipeline by Astex Pharmaceuticals Inc, 2021

Fallopian Tube Cancer – Pipeline by AstraZeneca Plc, 2021

Fallopian Tube Cancer – Pipeline by Aurigene Discovery Technologies Ltd, 2021

Fallopian Tube Cancer – Pipeline by Basilea Pharmaceutica Ltd, 2021

Fallopian Tube Cancer – Pipeline by Bayer AG, 2021

Fallopian Tube Cancer – Pipeline by BeiGene Ltd, 2021

Fallopian Tube Cancer – Pipeline by Bio-Path Holdings Inc, 2021

Fallopian Tube Cancer – Pipeline by Bio-Thera Solutions Ltd, 2021

Fallopian Tube Cancer – Pipeline by BioAtla Inc, 2021

Fallopian Tube Cancer – Pipeline by BioIntegrator Ltd, 2021

Fallopian Tube Cancer – Pipeline by BioInvent International AB, 2021

Fallopian Tube Cancer – Pipeline by BioNTech SE, 2021

Fallopian Tube Cancer – Pipeline by Boehringer Ingelheim International GmbH, 2021

Fallopian Tube Cancer – Pipeline by Bristol-Myers Squibb Co, 2021

Fallopian Tube Cancer – Pipeline by Celldex Therapeutics Inc, 2021

Fallopian Tube Cancer – Pipeline by Celsion Corp, 2021

Fallopian Tube Cancer – Pipeline by Celyad Oncology SA, 2021

Fallopian Tube Cancer – Pipeline by Clovis Oncology Inc, 2021

Fallopian Tube Cancer – Pipeline by Coherent Biopharma, 2021

Fallopian Tube Cancer – Dormant Projects, 2021

Fallopian Tube Cancer – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Fallopian Tube Cancer, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports